Several studies have shown a diagnostic role for endocan in kidney diseases, such as acute kidney injury , chronic kidney disease , and renal replacement therapy ; however, the results are conflicting, and the exact mechanism of endocan in kidney function has not fully determined [].
The fact that endocan was mostly increased in diabetic patients with other diseases compared with controls shows that endocan is more severely related to diabetes rather than these diseases. So, endocan is still a useful biomarker of diabetes in these patients. For sure, other studies with larger sample sizes are needed to confirm these findings.
Considering all these findings, a point of caution is that increased endocan levels could not be the only determining marker in the diagnosis of diabetes and predicting its future complications. Certainly, future studies assessing endocan levels in microvascular complications are needed to provide better insight into the use of endocan as a prognostic biomarker in diabetes.
Our study is the first systematic review and meta-analysis comparing the levels of endocan in diabetic patients with non-diabetic controls and investigating the correlation of endocan levels with complications in diabetic patients. While this systematic review can provide useful information about the role of endocan in diabetes and its complications, it has some limitations.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
New study reveals alarming impact of ultra-processed foods on cardiometabolic healthNew study reveals alarming impact of ultra-processed foods on cardiometabolic health UltraProcessedFood Cardiometabolic MetabolicSyndrome Diet Health UPFConsumption HealthImpact FoodChoices HealthyLiving Nutrition ATHjournal
Source: NewsMedical - 🏆 19. / 71 Read more »
Researchers identify jumping genes that can lead to rare syndrome in childrenA new family of DNA elements which control the activation of certain genes known to cause a rare disease known as MSL3 syndrome in children has been identified.
Source: medical_xpress - 🏆 101. / 51 Read more »
Embryonic vitamin D deficiency programs hematopoietic stem cells to induce type 2 diabetes - Nature CommunicationsEnvironmental conditions during pregnancy contribute to offspring metabolic disease. Here, the authors show that immune cells reprogrammed in utero by maternal vitamin D deficiency increase lifetime diabetes risk in the offspring and are sufficient to transplant diabetes.
Source: medical_xpress - 🏆 101. / 51 Read more »
Birthweight is associated with clinical characteristics in people with recently diagnosed type 2 diabetes - DiabetologiaAims/hypothesis Low birthweight is a risk factor for type 2 diabetes but it is unknown whether low birthweight is associated with distinct clinical characteristics at disease onset. We examined whether a lower or higher birthweight in type 2 diabetes is associated with clinically relevant characteristics at disease onset. Methods Midwife records were traced for 6866 individuals with type 2 diabetes in the Danish Centre for Strategic Research in Type 2 Diabetes (DD2) cohort. Using a cross-sectional design, we assessed age at diagnosis, anthropomorphic measures, comorbidities, medications, metabolic variables and family history of type 2 diabetes in individuals with the lowest 25% of birthweight (3700 g), compared with a birthweight of 3000–3700 g as reference, using log-binomial and Poisson regression. Continuous relationships across the entire birthweight spectrum were assessed with linear and restricted cubic spline regression. Weighted polygenic scores (PS) for type 2 diabetes and birthweight were calculated to assess the impact of genetic predispositions. Results Each 1000 g decrease in birthweight was associated with a 3.3 year (95% CI 2.9, 3.8) younger age of diabetes onset, 1.5 kg/m2 (95% CI 1.2, 1.7) lower BMI and 3.9 cm (95% CI 3.3, 4.5) smaller waist circumference. Compared with the reference birthweight, a birthweight of |3000 g was associated with more overall comorbidity (prevalence ratio [PR] for Charlson Comorbidity Index Score ≥3 was 1.36 [95% CI 1.07, 1.73]), having a systolic BP ≥155 mmHg (PR 1.26 [95% CI 0.99, 1.59]), lower prevalence of diabetes-associated neurological disease, less likelihood of family history of type 2 diabetes, use of three or more glucose-lowering drugs (PR 1.33 [95% CI 1.06, 1.65]) and use of three or more antihypertensive drugs (PR 1.09 [95% CI 0.99, 1.20]). Clinically defined low birthweight (|2500 g) yielded stronger associations. Most associations between birthweight and clinical characteristics appeared linear, and a hig
Source: medical_xpress - 🏆 101. / 51 Read more »
Chemotherapy-induced weight gain in early-stage breast cancer: a prospective matched cohort study reveals associations with inflammation and gut dysbiosis - BMC MedicineBackground Early-stage breast cancer patients treated with chemotherapy risk the development of metabolic disease and weight gain, which can result in increased morbidity and reduced quality of life in survivorship. We aimed to analyze changes within the gastrointestinal microbiome of early-stage breast cancer patients treated with and without chemotherapy to investigate a potential relationship between dysbiosis, a systemic inflammatory response, and resultant anthropomorphic changes. Methods We undertook an a priori analysis of serially collected stool and plasma samples from 40 patients with early-stage breast cancer who underwent adjuvant endocrine therapy only, adjuvant chemotherapy only, or both. Gut microbiota were assessed by metagenomic comparison of stool samples following deep sequencing. Inflammatory biomarkers were evaluated by proteomic analysis of plasma and measurement of fecal calprotectin. Body composition was investigated by dual-energy X-ray absorptiometry to determine biomass indices. Results As opposed to treatment with endocrine therapy only, chemotherapy resulted in statistically and clinically significant weight gain and an increase in the android to gynoid ratio of fat distribution. Patients treated with chemotherapy gained an average of 0.15% total mass per month, as opposed to a significantly different loss of 0.19% in those patients who received endocrine-only therapy. Concurrently, a twofold increase in fecal calprotectin occurred after chemotherapy that is indicative of interferon-dependent inflammation and evidence of colonic inflammation. These anthropomorphic and inflammatory changes occurred in concert with a chemotherapy-dependent effect on the gut microbiome as evidenced by a reduction in both the abundance and variety of microbial species. Conclusions We confirm the association of chemotherapy treatment with weight gain and potential deleterious anthropometric changes and suggest that alterations of bacterial flora may contribut
Source: BioMedCentral - 🏆 22. / 71 Read more »